ImmunoCAP Whole Allergens
Help Improve Certainty in Diagnosis

These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.

We offer the broadest selection of more than 550 specific IgE whole allergens and allergen mixes including foods, pollens, animal dander and epithelia, microorganisms, insect venoms, occupational allergens, and more, giving clinicians a higher level of diagnostic certainty. ImmunoCAP™ tests provide an objective measurement of the circulating allergen-specific IgE antibodies. Specific IgE antibodies appear as a result of exposure and following sensitization to an allergen.

 


 

Improve accuracy by combining case history with ImmunoCAP Whole Allergen testing1,2*

Confidence in the ability diagnose allergy has been shown to increase when ImmunoCAP Whole Allergen test results are added to clinical history.1,2

 

ImmunoCAP Specific IgE has excellent clinical performance:3**

  • 84 to 95% sensitivity
  • 85 to 94% specificity

*In patients with symptoms of eczema, wheeze and/or asthma, and rhinitis in primary care.

**Depending on the allergen

 

Quantitative test results you can trust, enabled through high-quality standards

We work hard to maintain the highest possible quality. Results should be accurate not only now, but also over time to enable clinicians to follow patient’s disease progression and adjust management when needed.

 

Our quality system and production process controls are designed to ensure allergen consistency, which enables ImmunoCAP tests to provide precise, reproducible, quantification of specific IgE antibodies, confirmed in multiple studies and quality schemes.4,5

  • Truly quantitative measuring range from 0.1-100 kUA/l.6,7
  • Limit of quantitation as low as 0.1 kUA/l.6,7
  • Consistent results with CV <15% for ImmunoCAP Specific IgE tests.4,5
  • Consistent test results over time among labs, systems, and lab-operators.4-6

 

ImmunoCAP values referenced in clinical diagnostic decision points cannot be applied to results from other diagnostic systems.8-11

 

Factors to consider for a final diagnosis

  • Age
  • Degree of atopy 
  • Allergen load
  • Type or sensitizing allergens
  • Previous symptoms
  • Other triggering factors

Quantitative specific IgE levels translates into clear clinical benefits

  • Follow patient´s allergic status over time—tolerance development.16,17
  • Early sensitization can be predictive of future allergies.14-16
  • Help diagnose allergy, identify the sensitizing allergen(s) and cross-reactivity.12

Specific IgE concentrations correlate with risk of symptomatic disease

The diagnostic value of quantitative specific IgE levels is visualized in a generic risk curve. This curve is based on thousands of ImmunoCAP Specific IgE test results and demonstrates the relationship between increasing IgE levels and the increasing probability of symptomatic allergy. A general rule of thumb is that the higher the IgE antibody value, the greater the probability of symptoms appearing when exposed to the allergen.12-14

Explore the full ImmunoCAP portfolio.
View Portfolio
Find an instrument to run ImmunoCAP tests.
View Phadia Laboratory Systems
Get scientific information on whole allergens, allergen mixes, and allergen components.
Visit Allergen Encyclopedia
References
  1. Duran-Tauleria, E., et al., The utility of specific immunoglobulin E measurements in primary care. Allergy, 2004. 59 Suppl 78: p. 35-41.
  2. Niggemann, B., M. Nilsson, and F. Friedrichs, Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. Pediatr Allergy Immunol, 2008. 19(4): p. 325-31.
  3. Johansson, S.G., ImmunoCAP Specific IgE test: an objective tool for research and routine allergy diagnosis. Expert Rev Mol Diagn, 2004. 4(3): p. 273-9.
  4. UKNEQAS for specific IgE: Pooled CV (%) during 2011-2017.
  5. Quality Club Specific IgE; pooled CV (%) during 2003-2017.
  6. van Hage, M., C. Hamsten, and R. Valenta, ImmunoCAP assays: Pros and cons in allergology. J Allergy Clin Immunol, 2017. 140(4): p. 974-977.
  7. Directions for use. ImmunoCAP specific IgE.
  8. Wood RA, Segall N, Ahlstedt, S et al. (2007) Accuracy of IgE antibody laboratory results. Ann Allergy Asthma Immunol. 99: 34-41.
  9. Wang J, Godbold JH, Sampson HA. (2008) Correlation of serum (IgE) tests performed by different assay systems. J Allergy Clin Immunol 121(5):1219–24.
  10. Cox L, Williams B, Sicherer, S et al. (2008) Pearls and pitfalls of allergic diagnostic testing:report from the American College of Allergy, Asthma and Immunology/American Academy of Allergy/Asthma and Immunology Specific IgE Test Task Force. Ann Allergy Asthma Immunol. 101(6):580-92.
  11. Boyce B, Assa’ad A, Wesley Burks A et al. (2010) Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 126(6 Suppl): S1-58.
  12. Soderstrom, L., et al., A further evaluation of the clinical use of specific IgE antibody testing in allergic diseases. Allergy, 2003. 58(9): p. 921-8.
  13. Sampson, H.A., Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol, 2001. 107(5): p. 891-6.
  14. Shek, L.P., et al., Determination of food specific IgE levels over time can predict the development of tolerance in cow's milk and hen's egg allergy. J Allergy Clin Immunol, 2004. 114(2): p. 387-91.
  15. Illi, S., et al., The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol, 2004. 113(5): p. 925-31.
  16. Eigenmann, P.A., et al., Testing children for allergies: why, how, who and when: an updated statement of the European Academy of Allergy and Clinical Immunology (EAACI) Section on Pediatrics and the EAACI-Clemens von Pirquet Foundation. Pediatr Allergy Immunol, 2013. 24(2): p. 195-209.
  17. Wood, R.A., The likelihood of remission of food allergy in children: when is the optimal time for challenge? Curr Allergy Asthma Rep, 2012. 12(1): p. 42-7.